<DOC>
	<DOCNO>NCT02760498</DOCNO>
	<brief_summary>To estimate clinical benefit REGN2810 monotherapy patient metastatic ( nodal distant ) cutaneous squamous cell carcinoma ( CSCC ) ( Group 1 ) unresectable locally advanced CSCC ( Group 2 ) , measure overall response rate ( ORR ) , accord central review .</brief_summary>
	<brief_title>Study REGN2810 Patients With Advanced Cutaneous Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<criteria>Key At least 1 measurable lesion Eastern Cooperative Oncology Group ( ECOG ) performance status ≤1 Adequate bone marrow function Adequate renal function Adequate hepatic function Archived newly obtain tumor material Patients must consent undergo biopsy externally visible CSCC lesion ( Group 2 ) Surgical radiological treatment lesion contraindicate Key Ongoing recent ( within 5 year ) evidence significant autoimmune disease require treatment systemic immunosuppressive treatment , may suggest risk immunerelated adverse event Prior treatment agent block PD1/PDL1pathway Prior treatment BRAF inhibitor Prior treatment immunemodulating agent within few 4 week prior first dose REGN2810 , associate immunemediated adverse event ≥ grade 1 within 90 day prior first dose REGN2810 , associate toxicity result discontinuation immunemodulating agent . Examples immunemodulating agent include therapeutic vaccine , cytokine treatment , agent target cytotoxic Tlymphocyte antigen 4 ( CTLA4 ) , 41BB ( CD137 ) , OX40 . Untreated brain metastasis ( es ) may consider active Immunosuppressive corticosteroid dos ( &gt; 10 mg prednisone daily equivalent ) within 4 week prior first dose REGN2810 Infection human immunodeficiency virus ( HIV ) and/or chronic/active infection hepatitis B virus hepatitis C virus History pneumonitis within last 5 year Allergic reaction acute hypersensitivity reaction attribute antibody treatment Known allergy doxycycline tetracycline Patients history solid organ transplant Any medical comorbidity , physical examination finding , metabolic dysfunction , clinical laboratory abnormality render patient unsuitable Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>